The cell banking outsourcing market has seen considerable growth due to a variety of factors.
• The cell banking outsourcing market has grown rapidly in recent years. It is expected to rise from $11.19 billion in 2024 to $12.89 billion in 2025, with a compound annual growth rate (CAGR) of 15.2%.
The growth drivers include the increase in chronic disease prevalence, government initiatives and regulatory support, and the expansion of banking services.
The cell banking outsourcing market is expected to maintain its strong growth trajectory in upcoming years.
• The cell banking outsourcing market is projected to reach $22.39 billion by 2029 at a CAGR of 14.8%.
Growth is attributed to the rising use of cellular products, demand for monoclonal antibodies, the adoption of stem cell therapies, an aging population, and dependence on cell-based therapies. Trends include product innovations, technological advancements, and biotech companies collaborating with specialized cell banking services.
The rising burden of chronic diseases is expected to boost the growth of the cell banking outsourcing market. Chronic diseases, such as heart disease and diabetes, require ongoing management and are becoming more prevalent due to lifestyle changes and aging populations. Outsourcing cell banking services can enhance research and development efforts to address chronic conditions by providing specialized expertise and infrastructure. For example, in July 2023, the Department of the Treasury reported that almost half of Australians (46.6%) had one or more chronic diseases in 2020–21. This rising chronic disease burden will accelerate the growth of the market.
The cell banking outsourcing market covered in this report is segmented –
1) By Type: Master Cell Banking, Working Cell Banking, Viral Cell Banking
2) By Cell Type: Stem Cell Banking, Non-Stem Cell Banking
3) By Phase: Bank Storage, Bank Characterization And Testing, Bank Preparation
Subsegments:
1) By Master Cell Banking: Human Master Cell Bank, Animal Master Cell Bank
2) By Working Cell Banking: Human Working Cell Bank, Animal Working Cell Bank
3) By Viral Cell Banking: Virus Bank For Vaccine Production, Viral Vector Bank For Gene Therapy, Adenovirus Bank
In the cell banking outsourcing market, companies are focusing on developing advanced solutions such as single-cell potency characterization platforms. These platforms enable precise analysis of individual cell potency within a population. For instance, in January 2024, Italy-based Cellply Srl launched VivaCyte, a fully automated single-cell potency characterization platform designed to accelerate cell therapy research. This platform provides rapid, reproducible analysis of immune cell functionality and is designed to shorten development times and reduce risks.
Major companies operating in the cell banking outsourcing market are:
• LabCorp Drug Development
• SGS Life Sciences
• Lonza Group Ltd.
• WuXi AppTec
• Charles River Laboratories
• Sigma-Aldrich Co. Ltd.
• Covance Inc.
• Global Stem Inc.
• LifeCell
• Cryoviva India
• Sartorius AG
• Bio Reliance
• CordLife
• Reliance Life Sciences
• Cryo-Cell International Inc.
• Toxikon Corp.
• Cleancells
• Clean Biologics
• Texcell
• PX’Therapeutics SA
• Goodwin Biotechnology Inc.
• Transcell Biolife Pvt Ltd.
• Perfectus Biomed Limited
• BioStorage Technologies Inc.
North America was the largest region in the cell banking outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell banking outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.